Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
出版年份 2014 全文链接
标题
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 7, Pages 943-954
出版商
Informa Healthcare
发表日期
2014-04-21
DOI
10.1517/13543784.2014.911839
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 5-flourouracil (5FU) shortage: Clinical implications and costs in a single month.
- (2017) Shweta Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
- (2015) Håkon Reikvam et al. Oncotarget
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
- (2014) Alexandre Puissant et al. CANCER CELL
- Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
- (2014) Wen-Hsing Lin et al. PLoS One
- New agents: Great expectations not realized
- (2013) Jeffrey E. Lancet BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Emergence of crenolanib for FLT3-mutant AML
- (2013) A. T. Fathi BLOOD
- Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
- (2013) E. I. Zimmerman et al. BLOOD
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
- (2013) C. C. Smith et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
- (2013) Neil P. Shah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD
- (2013) Koichi Takahashi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect
- (2013) Håkon Reikvam et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
- (2013) S. D. Baker et al. CLINICAL CANCER RESEARCH
- Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy
- (2013) Naval Daver et al. Clinical Lymphoma Myeloma & Leukemia
- An update on clinical trials of targeted therapies in thyroid cancer
- (2013) Sigurdis Haraldsdottir et al. CURRENT OPINION IN ONCOLOGY
- Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
- (2013) Enrico Derenzini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity
- (2013) Håkon Reikvam et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
- (2013) Sabine Kayser et al. LEUKEMIA & LYMPHOMA
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
- (2013) Casey B. Williams et al. PHARMACOTHERAPY
- Inhibition of the PI3K/Akt/GSK3 Pathway Downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD Downregulates DNA Damage-Induced Chk1 Activation as Well as G2/M Arrest and Prominently Enhances Induction of Apoptosis
- (2013) Tetsuya Kurosu et al. PLoS One
- Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update
- (2013) Bei Hu et al. Expert Review of Hematology
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
- (2012) A. Sexauer et al. BLOOD
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation
- (2012) Elisabeth Zirm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment
- (2012) Linhua Jin et al. CANCER LETTERS
- Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2012) M. C. Heinrich et al. CLINICAL CANCER RESEARCH
- Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
- (2012) Salut Brunet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
- (2012) E Weisberg et al. LEUKEMIA
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
- (2011) Manish Sharma et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- FLT3 inhibitors in the treatment of acute myeloid leukemia
- (2011) Naveen Pemmaraju et al. CANCER
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
- (2011) Hiroto Inaba et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
- (2011) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
- (2011) Marina Y. Konopleva et al. JOURNAL OF CLINICAL ONCOLOGY
- Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia
- (2011) Christoph Röllig et al. LEUKEMIA & LYMPHOMA
- Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
- (2011) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
- (2011) S Hart et al. Blood Cancer Journal
- Bench to Bedside Targeting of FLT3 in Acute Leukemia
- (2010) Keith W. Pratz et al. CURRENT DRUG TARGETS
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
- (2010) K W Pratz et al. LEUKEMIA
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
- (2010) Michael Crump et al. LEUKEMIA & LYMPHOMA
- mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
- (2010) Weina Chen et al. Molecular Cancer
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
- (2009) Marina Konopleva et al. DRUG RESISTANCE UPDATES
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
- (2008) W Zhang et al. LEUKEMIA
- Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia
- (2008) N.N. Safaian et al. LEUKEMIA RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now